Clinical Trial Update: A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of BMN053 for Duchenne muscular dystrophy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• BMN053

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: TERMINATED